(Reuters) - Catalent has agreed to sell its oral drug development and small-scale manufacturing facility in Somerset, New ...

Catalent, Inc. (NYSE: CTLT), the leader in enabling the development and supply of better treatments for patients worldwide, ...

Catalent (NYSE:CTLT) is selling its oral solids development and small-scale manufacturing facility in Somerset, New Jersey to ...

Somerset facility State-of-the art facility for clinical and commercial manufacturing of oral dosage forms. Ghent, Belgium, ...

Sen. Elizabeth Warren urges FTC to scrutinize Novo Nordisk's $16.5 billion acquisition of Catalent over concerns of increased ...

NEW YORK (Reuters) -U.S. Senator Elizabeth Warren has asked antitrust regulators to scrutinize a $16.5 billion deal in which ...

Awaiting a potential acquisition by Novo Holdings, Catalent is giving its contract manufacturing compatriot a boost as Ardena ...

On Monday, Catalent Inc (CTLT) stock saw a modest uptick, ending the day at $60.65 which represents a slight increase of $0.20 or 0.33% from the prior close of $60.45. The stock opened at $60.5 and ...

Catalent entered into a definitive agreement to sell its oral solids development and small-scale manufacturing facility in ...

Catalent, Inc. (CTLT), a provider of advanced delivery technologies and development solutions for drugs, biologics, and consumer ...

Senator Elizabeth Warren told the Federal Trade Commission that the acquisition of contract manufacturer Catalent could ...

Ardena inks agreement to acquire Catalent’s state-of-the-art facility in Somerset, New Jersey: Ghent, Belgium Tuesday, October 15, 2024, 16:00 Hrs [IST] Ardena, a specialist pha ...